Please login to the form below

anaesthetics

This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.

Acacia finally gets FDA okay for first product Barhemsys

Meanwhile, the UK company is also preparing for a possible approval by 5 April of ByFavo (remimazolam), an ultra-short-acting and reversible intravenous benzodiazepine sedative/anaesthetic for use during procedural

Latest news

Sandoz expands into Japan with €400m Aspen deal

Aspen’s portfolio consists of approximately 20 off-patent medicines, including anaesthetics like Xylocaine and speciality brands such as immune suppressing drug Imuran for multiple sclerosis patients.
Stung by critics, J&J says antidepressant Spravato saves money

It is a single isomer form of ketamine, a low-cost anaesthetic, and ICER says the similarity between the two drugs “raises issues for all stakeholders about how to consider
J&J’s Spravato breaks depression drought at FDA

The green light for nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine – is for use of the drug as an add-on to oral antidepressants in people with
Gyroscope's gene therapy given to first dry AMD patient

GT005 was administered under a local anaesthetic by Robert MacLaren, an ophthalmology specialist at Oxford Eye Hospital.
FDA panel backs J&J’s new-class antidepressant

The nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine that has the proposed name Spravato – was backed by a 14-2 vote by an FDA advisory committee yesterday

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.
Deal Watch September 2016

500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].
Deal Watch June 2016

Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and
Pharma deals in June 2015

Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.
Pharma deals during March 2014

Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

Addressing Climate Impact: The Healthcare Paradox

Similarly, some procedures are particularly carbon intensive. Hospitals have been exploring solutions ranging from retrofitting heat recovery technology to dialysis machines, to switching operating room anaesthetics, which account for almost a
It’s all about patient outcomes… right?

general anaesthetic. ... Routledge; London, UK, 2002. Snow SJ. Blessed Days of Anaesthesia: How Anaesthetics Changed the World.
"Legal highs" ruling leaves illegal labs laughing

These include the anaesthetic nitrous oxide, or laughing gas. . N2O has been used as a recreational drug since 1799, when 'laughing gas parties' were popular among the ruling classes.
Healthcare 2025: what the future holds for pharma

This was led by major advances in three core areas:. Health: Access to innovative medicines, surgery and anaesthetics, clean air and water.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....